In late June, Pardes Biosciences announced an agreement to merge with a special purpose acquisition company (SPAC) sponsored by Foresite Capital, raising $276 million. The funds are intended to aid the development of PBI-0451 and the firm’s method of using reversible covalent chemistry to design drugs . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge